Li Kang Biomedical Co., Ltd. (6242) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Li Kang Biomedical Co., Ltd. (6242:TWSE), powered by AI.

Current Price
$38.15
Sector
Consumer Cyclical
What is the Li Kang Biomedical Co., Ltd. stock price forecast?

Li Kang Biomedical Co., Ltd. is currently trading at $38.15. View real-time AI analysis on Alpha Lenz.

What is Li Kang Biomedical Co., Ltd. insider trading activity?

View the latest insider trading data for Li Kang Biomedical Co., Ltd. on Alpha Lenz.

What is Li Kang Biomedical Co., Ltd.'s P/E ratio?

View Li Kang Biomedical Co., Ltd.'s valuation metrics on Alpha Lenz.

Li Kang Biomedical Co., Ltd.

TWSE · 6242
NT$38.15+0.00(+0.00%)
Ask about Li Kang Biomedical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Li Kang Biomedical Co., Ltd.'s ROE is 9.7%. Explore profitability and growth together.

Ask for details

Company Overview

Li Kang Biomedical Co., Ltd. is a consumer-focused company specializing in the manufacture and sale of supplements, cosmeceuticals, and hygienic drink products. Originally established in 1982 and based in Tainan City, Taiwan, the company underwent a significant transition in 2014 when it shifted its business model from producing technology-related wiring and communication products to focusing on health and wellness sectors, particularly through its experience in Chinese herbal medicine. The company’s core operations integrate manufacturing with innovative channel strategies such as tourism factories, telemarketing, and partnerships with traditional Chinese medicine pharmacies. These specialized sales channels are designed to enhance brand reach and consumer accessibility, especially by leveraging the rising demand for hygienic drinks rooted in traditional medicinal materials. In addition to its product offerings, Li Kang Biomedical is involved in managing and consulting for tourism factory businesses, assisting conventional manufacturers in transitioning to service and tourism-oriented models. This multifaceted approach positions Li Kang Biomedical as a unique player bridging traditional wellness, modern retail, and experiential industry sectors within Taiwan’s consumer discretionary landscape.

SectorConsumer Cyclical
IndustryTravel Services
Employees122

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$589.21MRevenue
0.00Shares Out
122Employees

Margins

67.59%Gross
19.21%EBITDA
16.68%Operating
17.66%Pre-Tax
14.23%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

-4.86%Rev 3Yr
5.23%Rev 5Yr
-10.56%Op Inc 3Yr
3.96%Op Inc 5Yr
-9.23%Net Inc 3Yr
3.89%Net Inc 5Yr

Returns

7.88%ROA
9.71%ROE
9.81%ROIC

Financial Health

NT$42.92MCash & Cash Equivalents
NT$178.89MNet Debt
25.46%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Li Kang Biomedical Co., Ltd. (ticker: 6242) is a company listed on TWSE in the Consumer Cyclical sector (Travel Services). It has approximately 122 employees.

The current price is 38.15 with a P/E ratio of -x and P/B of -x.

ROE is 9.71% and operating margin is 16.68%. Annual revenue is $589M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Li Kang Biomedical Co., Ltd. (6242) Stock Forecast 2026 $38.15 — Price, Financials & Analyst Targets | Alpha Lenz